As the report also implies the sector is somewhat chaotic (when is it not?) and even if the Justice Dept gives various deals the go ahead the magic moment may have already passed.

 

Or in corporate speak .

California-based MedMen noted in a news release announcing the cancellation that “regulatory hurdles at the federal and state level … delayed the integration and realization of synergies that were initially factored into the value of the transaction to the company.”

 

Read full report

Antitrust cloud lifting on cannabis M&A deals, but will some be renegotiated – or even abandoned?